The dramatic ramp up comes at an awkward time, however. Early adopters of China’s vaccines have seen dramatic surges in COVID-19 cases—despite high vaccination rates—and are now backing away from the country’s offerings.
In Bahrain, for instance, officials are now offering high-risk people who have already received two doses of China’s Sinopharm vaccine a third vaccine dose—but one made by Pfizer-BioNTech. The apparent vote of no confidence by officials is striking: Bahrain was one of the first countries to back and rollout Sinopharm’s vaccine, and it has had a highly successful vaccination campaign. Nearly 58 percent of the Persian Gulf country has received at least one dose of a vaccine, and most of the vaccines given in Bahrain are from Sinopharm. But the country is now seeing its worst wave of COVID-19 yet and the government has recently issued a two-week lockdown to try to get transmission under control.
The Seychelles went through a similar struggle. The archipelago saw a dramatic spike in cases in mid-May, despite having around 70 percent of its population vaccinated with at least one dose. Like Bahrain, the Seychelles had largely relied on the Sinopharm vaccine.
Dubai, which has also relied on Sinopharm’s vaccine, is now quietly offering residents who have been fully vaccinated with the Sinopharm vaccine the opportunity to get re-vaccinated with the Pfizer-BioNTech vaccine, according to The Wall Street Journal.